Evergreen Wealth Management LLC Has $2.64 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Evergreen Wealth Management LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 73.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,464 shares of the medical research company's stock after purchasing an additional 3,592 shares during the period. Amgen makes up about 1.6% of Evergreen Wealth Management LLC's holdings, making the stock its 23rd biggest position. Evergreen Wealth Management LLC's holdings in Amgen were worth $2,637,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pinney & Scofield Inc. purchased a new stake in Amgen in the 4th quarter valued at approximately $26,000. First Pacific Financial lifted its stake in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE lifted its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in Amgen in the 4th quarter valued at approximately $36,000. Finally, Legacy Investment Solutions LLC lifted its stake in Amgen by 46.9% in the 4th quarter. Legacy Investment Solutions LLC now owns 141 shares of the medical research company's stock valued at $37,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AMGN shares. Piper Sandler reaffirmed an "overweight" rating and issued a $328.00 target price on shares of Amgen in a research note on Friday, June 27th. Mizuho increased their price target on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Royal Bank Of Canada reduced their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Finally, Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Amgen has an average rating of "Hold" and a consensus target price of $307.82.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.76% of the company's stock.

Amgen Stock Performance

NASDAQ AMGN traded down $3.49 during trading hours on Friday, reaching $294.76. The company's stock had a trading volume of 1,967,651 shares, compared to its average volume of 2,842,923. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The business has a 50-day simple moving average of $285.90 and a 200 day simple moving average of $289.35. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock has a market cap of $158.50 billion, a PE ratio of 26.89, a PEG ratio of 2.66 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. During the same quarter in the previous year, the company posted $3.96 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.